Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.c

Hemoptysis

Publications

Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, Fukuoka M

Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.

Cancer science. 2016;107(12):1837-1842

Okamoto K, Okamoto I, Miyazaki M, Tanaka K, Kaneda H, Nakagawa K

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.

Investigational new drugs. 2013;31(5):1364-6

Reck M, Barlesi F, Crinò L, Henschke CI, Isla D, Stiebeler S, Spigel DR

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(5):1111-1120

Hapani S, Sher A, Chu D, Wu S

Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.

Oncology. 2010;79(1-2):27-38

Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

The Lancet. Oncology. 2010;11(8):733-40

Cho YJ, Murgu SD, Colt HG

Bronchoscopy for bevacizumab-related hemoptysis.

Lung cancer (Amsterdam, Netherlands). 2007;56(3):465-8

Herbst RS, Sandler AB

Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?

The oncologist. 2004;9 Suppl 1:19-26

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(11):2184-91